Table 1.

Risk factors for early vomiting after dosing of antimalarial therapy in young children, Uganda^*

Risk groups	No. early vomiters/total treatments in first group (%)	No. early vomiters/total treatments in second group (%)	RR for early vomiting† (first group vs. second group) (95% CI)	P
Age < 18 months vs. age ≥ 18 months	48/358 (13.4)	4/110 (3.6)	3.27 (1.24–8.59)	0.02
DP use vs. AL use (not breastfeeding)	9/133 (6.8)	9/128 (7.0)	1.03 (0.43–2.48)	0.94
DP use vs. AL use (breastfeeding)	27/107 (25.2)	7/100 (7.0)	3.35 (1.67–6.70)	0.001

^*RR = relative risk; CI = confidence interval; DP = dihydroartemisinin-piperaquine; AL = artemether-lumefantrine.

^†RR and CIs were generated by using generalized estimating equations adjusted for repeated measures in the same patients with a multivariate model including antimalarial drug, age, breastfeeding, and an interaction term between breastfeeding and antimalarial treatment.